Shares of Cardiol Therapeutics Inc. (NASDAQ:CRDL – Get Free Report) have earned an average rating of “Buy” from the seven analysts that are currently covering the company, MarketBeat reports. Five research analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $8.40.
A number of research firms have weighed in on CRDL. HC Wainwright reaffirmed a “buy” rating and set a $9.00 price target on shares of Cardiol Therapeutics in a research note on Wednesday, December 18th. Rodman & Renshaw began coverage on Cardiol Therapeutics in a report on Tuesday, January 28th. They issued a “buy” rating and a $7.00 target price on the stock. Finally, RODMAN&RENSHAW raised Cardiol Therapeutics to a “strong-buy” rating in a research report on Tuesday, January 28th.
Check Out Our Latest Research Report on CRDL
Institutional Investors Weigh In On Cardiol Therapeutics
Cardiol Therapeutics Price Performance
CRDL opened at $1.41 on Tuesday. Cardiol Therapeutics has a 1 year low of $0.96 and a 1 year high of $3.12. The company’s 50 day simple moving average is $1.36 and its 200 day simple moving average is $1.77. The stock has a market capitalization of $116.48 million, a PE ratio of -3.62 and a beta of 0.89. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.49 and a current ratio of 2.49.
About Cardiol Therapeutics
Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
Recommended Stories
- Five stocks we like better than Cardiol Therapeutics
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- ServiceNow Stock Slips, But AI Expansion Signals Long-Term Gains
- How to trade using analyst ratings
- Microsoft and Meta’s AI Investment Plans Are Full Steam Ahead
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Beyond Self-Driving Cars: Factory Automation Takes Center Stage
Receive News & Ratings for Cardiol Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiol Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.